Sign In
Buy KURA
Kura Oncology Earnings Calls
| Release date | Nov 04, 2025 |
| EPS estimate | -$0.570 |
| EPS actual | -$0.85 |
| EPS Surprise | -49.12% |
| Revenue estimate | 81.475M |
| Revenue actual | 20.75M |
| Revenue Surprise | -74.53% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.150 |
| EPS actual | -$0.750 |
| EPS Surprise | -600.00% |
| Revenue estimate | 64.949M |
| Revenue actual | 15.288M |
| Revenue Surprise | -76.46% |
| Release date | May 01, 2025 |
| EPS estimate | -$0.510 |
| EPS actual | -$0.660 |
| EPS Surprise | -29.41% |
| Revenue estimate | 66.662M |
| Revenue actual | 14.108M |
| Revenue Surprise | -78.84% |
| Release date | Feb 26, 2025 |
| EPS estimate | -$0.650 |
| EPS actual | -$0.220 |
| EPS Surprise | 66.15% |
| Revenue estimate | 57.962M |
| Revenue actual | 53.883M |
| Revenue Surprise | -7.04% |
Last 4 Quarters for Kura Oncology
Below you can see how KURA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 26, 2025 |
| Price on release | $7.77 |
| EPS estimate | -$0.650 |
| EPS actual | -$0.220 |
| EPS surprise | 66.15% |
| Date | Price |
|---|---|
| Feb 20, 2025 | $8.15 |
| Feb 21, 2025 | $8.25 |
| Feb 24, 2025 | $7.88 |
| Feb 25, 2025 | $7.88 |
| Feb 26, 2025 | $7.77 |
| Feb 27, 2025 | $7.65 |
| Feb 28, 2025 | $7.71 |
| Mar 03, 2025 | $7.25 |
| Mar 04, 2025 | $7.33 |
| 4 days before | -4.66% |
| 4 days after | -5.66% |
| On release day | -1.54% |
| Change in period | -10.06% |
| Release date | May 01, 2025 |
| Price on release | $6.49 |
| EPS estimate | -$0.510 |
| EPS actual | -$0.660 |
| EPS surprise | -29.41% |
| Date | Price |
|---|---|
| Apr 25, 2025 | $6.43 |
| Apr 28, 2025 | $6.51 |
| Apr 29, 2025 | $6.52 |
| Apr 30, 2025 | $6.56 |
| May 01, 2025 | $6.49 |
| May 02, 2025 | $6.47 |
| May 05, 2025 | $6.72 |
| May 06, 2025 | $5.79 |
| May 07, 2025 | $5.65 |
| 4 days before | 0.93% |
| 4 days after | -13.02% |
| On release day | -0.308% |
| Change in period | -12.21% |
| Release date | Aug 07, 2025 |
| Price on release | $5.96 |
| EPS estimate | $0.150 |
| EPS actual | -$0.750 |
| EPS surprise | -600.00% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $6.02 |
| Aug 04, 2025 | $6.32 |
| Aug 05, 2025 | $6.36 |
| Aug 06, 2025 | $6.03 |
| Aug 07, 2025 | $5.96 |
| Aug 08, 2025 | $5.54 |
| Aug 11, 2025 | $5.54 |
| Aug 12, 2025 | $6.20 |
| Aug 13, 2025 | $6.49 |
| 4 days before | -1.00% |
| 4 days after | 8.89% |
| On release day | -7.05% |
| Change in period | 7.81% |
| Release date | Nov 04, 2025 |
| Price on release | $9.96 |
| EPS estimate | -$0.570 |
| EPS actual | -$0.85 |
| EPS surprise | -49.12% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $10.26 |
| Oct 30, 2025 | $10.44 |
| Oct 31, 2025 | $10.27 |
| Nov 03, 2025 | $9.77 |
| Nov 04, 2025 | $9.96 |
| Nov 05, 2025 | $9.94 |
| Nov 06, 2025 | $10.16 |
| Nov 07, 2025 | $9.86 |
| Nov 10, 2025 | $10.32 |
| 4 days before | -2.92% |
| 4 days after | 3.61% |
| On release day | -0.201% |
| Change in period | 0.585% |
Kura Oncology Earnings Call Transcript Summary of Q3 2025
Kura Oncology provided updates on its lead menin inhibitor ziftomenib and its farnesyl transferase inhibitor (FTI) programs, commercial readiness, and financials. Key clinical/regulatory items: the FDA review for ziftomenib in relapsed/refractory NPM1‑mutant AML remains on track with a PDUFA date of November 30, 2025; KOMET‑001 data were published in JCO and Kura will present expanded combination data at ASH (oral presentations) with more mature follow‑up; KOMET‑017 Phase III frontline registrational trials (intensive 7+3 and non‑intensive ven/aza combinations) are enrolling globally; combination cohorts with FLT3 inhibitors and other agents are ongoing. Commercial readiness: joint Kura/Kyowa Kirin (1K) field teams are trained and positioned for launch, payer engagements and limited distribution setup are complete, and the companies expect rapid access upon approval. FTI portfolio: darlafarnib and tipifarnib combinations showed manageable safety and encouraging anti‑tumor activity (notable ORRs in RCC and PIK3CA‑dependent HNSCC), and the FTI platform is viewed as a strategic growth pillar. Financials: Q3 collaboration revenue from Kyowa Kirin was $20.8M; R&D and G&A expenses rose year over year; net loss was $74.1M in Q3; pro forma cash including recent milestone receipts was $609.7M as of Sept 30, 2025 (company expects runway into 2027 on current plans and additional near‑term milestone payments of roughly $315M forthcoming). Market/competitive: management emphasized a differentiated benefit‑risk and combinability profile versus other menin inhibitors (discussion also addressed competitor labeling with a QTc black box and its potential impact). Upcoming catalysts: PDUFA (Nov 30, 2025), ASH oral presentations and virtual investor event (Dec 8), ongoing frontline trial enrollment and multiple 2026 data readouts/expansions for FTI combos.
